Gary Pace Buys 30,000 Shares of CRDF

Gary Pace made a significant move in CRDF by purchasing 30,000 shares on June 18, 2026. The shares were bought at an average price of $1.22 each, resulting in a total transaction value of $36,600. This insider buying activity was not part of a pre-planned trading program.

Insider Buying and Selling at Cardiff Oncology, Inc.

On June 18, 2026, Gary Pace acquired 30,000 shares of CRDF at an average price of $1.22 per share, amounting to $36,600. This transaction was not conducted under a Rule 10b5-1 trading plan. Additionally, on the same day, CRDF's CEO, Mani Mohindru, purchased 24,703 shares at $1.21 each. Earlier, on June 11, 2026, several insiders, including Gary Pace, acquired 40,565 shares, though the price was not disclosed.

Other Institutional Activity in CRDF

In recent activity, BlackRock, Inc. reduced its stake in CRDF by 62,227 shares, leaving it with 3,981,387 shares valued at approximately $6,449,847. Vanguard Capital Management LLC opened a new position, acquiring 2,855,966 shares worth about $4,626,665. Meanwhile, Laurion Capital Management LP maintained its holding at 2,646,738 shares, valued at $4,287,716. Acorn Capital Advisors, LLC reduced its stake by 200,000 shares, bringing its total to 1,762,084 shares worth around $2,854,576. Geode Capital Management, LLC increased its holdings by 76,648 shares, ending with 1,599,663 shares valued at $2,592,106.

Cardiff Oncology, Inc. Stock Up 38.3%

Shares of CRDF traded at $1.21 on Monday. The stock has seen varied institutional activity, reflecting its current market dynamics. As of now, the company does not have a meaningful P/E ratio, given its lack of profitability.

Analysts Set New Price Targets

On June 3, 2026, Craig-Hallum downgraded CRDF to a hold rating with a price target of $2. Piper Sandler maintained its buy rating on February 25, 2026, with a target of $6. HC Wainwright & Co. reiterated its buy rating on January 28, 2026, with a target of $10. The consensus rating suggests a mixed outlook, with a range of price targets reflecting differing analyst perspectives.

About CRDF

CRDF is a biotechnology company focused on developing innovative treatments for cancer and other serious diseases. The company is dedicated to advancing its pipeline of drug candidates through clinical trials to bring new therapies to patients in need. Headquartered in the United States, CRDF continues to research and develop potential solutions in the healthcare sector.

Bottom Line

Gary Pace's recent purchase of CRDF shares is a notable insider move that investors may watch closely. The activity comes amid varied institutional interest and a spectrum of analyst opinions. As always, it's important to remember that insider transactions are reported after the fact and may not indicate future performance.